Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2820579 | Genomics | 2015 | 7 Pages |
Abstract
DNA methylation variations in gene promoter regions are well documented tumor-specific alterations in human malignancies including colon cancer, which may influence tumor behavior and clinical outcome. As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable. Here, we describe that DNA methylation levels at CpG loci of hyaluronoglucosaminidase 2 (HYLA2) could be used to identify stage II and III colon cancer patients who are most likely to benefit from 5-flourouracil (5-FU) chemotherapy with respect to overall survival and progression-free survival.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Katrin Pfütze, Axel Benner, Michael Hoffmeister, Lina Jansen, Rongxi Yang, Hendrik Bläker, Esther Herpel, Alexis Ulrich, Cornelia M. Ulrich, Jenny Chang-Claude, Hermann Brenner, Barbara Burwinkel,